Warfarin Dose Adjustment for INR 1.97
Continue warfarin at 5 mg daily without dose adjustment and recheck INR in 3-5 days. Your INR of 1.97 is approaching but has not yet reached the therapeutic range of 2.0-3.0 after only 7 days of therapy, which is expected during the initiation phase.
Rationale for This Recommendation
Your current INR of 1.97 falls just below the standard therapeutic target range of 2.0-3.0 1. According to established guidelines, when the INR is above the therapeutic range but less than 5, dose adjustments are warranted 2. However, your INR is below, not above, the therapeutic range, which represents a fundamentally different clinical scenario.
Why Not Increase the Dose Yet
- Seven days is insufficient time to reach steady state: Warfarin takes approximately 4-5 days for the INR to reflect dose changes 2. You've only been on therapy for 7 days, and your INR is already approaching therapeutic levels
- Risk of overshooting: Increasing the dose prematurely could result in a supratherapeutic INR (>3.0), which significantly increases bleeding risk 2
- Natural trajectory: An INR of 1.97 after 7 days suggests you're responding appropriately to 5 mg daily and will likely reach 2.0-3.0 within the next few days without adjustment
Important Monitoring Points
Recheck your INR in 3-5 days. At that point:
- If INR is 2.0-3.0: Continue 5 mg daily and monitor weekly until stable
- If INR remains <2.0: Increase dose by 10-20% (to 5.5-6 mg daily) and recheck in 3-5 days
- If INR >3.0: Reduce dose by 10-20% (to 4-4.5 mg daily) and recheck in 3-5 days
Critical Caveats
Your aPTT of 31.9 seconds is normal and irrelevant to warfarin monitoring. Warfarin is monitored exclusively by INR, not aPTT 3. The aPTT measures heparin effect and the intrinsic pathway; warfarin affects the extrinsic pathway measured by PT/INR. Do not use aPTT to guide warfarin dosing.
Factors that could necessitate earlier dose adjustment:
- Active thrombosis requiring urgent therapeutic anticoagulation
- High-risk conditions (mechanical heart valve, recurrent VTE)
- Known warfarin resistance or rapid metabolism
Avoid these common errors:
- Making frequent dose changes before steady state is reached (leads to INR instability)
- Using aPTT to guide warfarin therapy
- Aggressive dose escalation in the first 1-2 weeks (increases bleeding risk)
The FDA label emphasizes individualized dosing based on INR response 1, and the therapeutic target for most indications is INR 2.0-3.0 1. Your current trajectory suggests appropriate response to your current dose.